The relationship between androgens concentrations (testosterone and dehydroepiandrosterone sulfate) and metabolic syndrome in non-obese elderly men;Współzależność pomiȩdzy stȩżeniami androgenów (testosteronu i siarczanu dehydroepiandrosteronu) a zespołem metabolicznym u starszych, nieotyłych mȩżczyzn

Endokrynologia Polska

Volumn 58, Issue 6, 2007, Pages 496-504

  Rabijewski, Michał ^a   Papierska, Lucyna ^a   Kozakowski, Jarosław ^a   Zgliczyñski, Wojciech ^a  

^a MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

DHEA S; Men; Metabolic syndrome; Testosterone

Indexed keywords

PRASTERONE SULFATE; TESTOSTERONE; TRIACYLGLYCEROL;

AGED; ARTICLE; BLOOD; BODY MASS; HUMAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTOR;

AGED; BODY MASS INDEX; DEHYDROEPIANDROSTERONE SULFATE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS; TESTOSTERONE; TRIGLYCERIDES;

EID: 43549127177     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607. (Pubitemid 19004941)
2. Expert Panel on Detection, Evaluation, and Treatment of High Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
3. Lakka HM, Laksonen DE, Lakka TA i wsp. Metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 2882: 709-2716.
4. Reusch JE. Current concepts in insulin resistance, type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiol 2002; 90: 19G-26G. (Pubitemid 35266677)
5. Marin P, Arver S. Androgens and abdominal obesity. J Clin Endocrinol Metab 1998; 12: 441-453.
6. Barrett-Connor E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men. A prospectve population-based study. Circulation 1988; 78: 539-545.
7. Oh JY, Barrett-Connor E, Wedick NM i wsp. Endogenous sex hormones and the development of type 2 diabetes in elder men and women; the Rancho Bernardo Study. Diabetes Care 2002; 25: 55-60. (Pubitemid 41070783)
8. Abate N, Haffner SM, Garg A i wsp. Sex steroids hormones, upper obesity and insulin resistance. J Clin Endocrinol Metab 2002; 87: 4522-4527. (Pubitemid 35247035)
9. Haffner SM, Valdez RA, Mykkanen L i wsp. Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentration in nondiabetic men. Metabolism 1994; 43: 599-603. (Pubitemid 24145467)
10. Haffner SA, Valdez RA, Stern MP i wsp. Obesity, body fat distribution and sex hormones in men. Int J Obes Relat Metab Disord 1993; 37: 643-649. (Pubitemid 23340277)
11. Haffner SM, Karhapaa P, Mykkanen L i wsp. Insulin resistance, body fat distribution, and sex hormones in men. Diabetes 1994; 43: 212-219. (Pubitemid 24033674)
12. Tchernof A, Labrie F, Belanger A i wsp. Relationship between endogenous steroid hormones, sex-binding globulin and lipo-protein levels in men; contribution of visceral obesity, insulin levels and other metabolic variables. Atherosclerosis 1997; 133: 235-244. (Pubitemid 27373501)
13. Vermeulen A, Goemaere S, Kaufman JM i wsp. Testosterone, body composition and aging. J Endocrinol Invest 1999; 22: 110-116.
14. Vermeulen A, Goemaere S, Kaufman JM i wsp. Sex hormones, body composition and aging. The Aging Male 1999; 2: 8-15. (Pubitemid 29305448)
15. Feldman HA, Longcope C, Derby C i wsp. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from Massachusetts Male Aging Study. J Clin Endocrinol Metab 2002; 87: 589-598. (Pubitemid 34158223)
16. Kupelian V, Page ST, Araujo AB i wsp. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006; 1: 843-850. (Pubitemid 43357748)
17. Paolisso G, Ammendolas S, Rotondi M i wsp. Insulin resistance and advancing age: what role for dehydroepiandrosterone sulfate? Metabolism 1997; 46: 1281-1286. (Pubitemid 27473511)
18. Laaksonen DE, Niskanen L, Punnonen K i wsp. Sex hormoens, inflamation and the metabolic syndrome: a population-based study. Eur J Endocrinol 2003; 149: 601-608. (Pubitemid 38054707)
19. Jankowska EWA, Medras M, Rogucka EAA. Body mass index, waist/hip ratio and androgen-estrogen activity in younger versus older Polish men. Aging Male 2000; 3: 177-184. (Pubitemid 32115867)
20. Muller M, Grobbee DE, den Tonkelaar I i wsp. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005; 90: 2618-2623. (Pubitemid 40686299)
21. Zgliczynski S. Andropauza. W: Zgliczynski S, Zgliczynski W (red.). Standardy Endokrynologii. Narodowa Fundacja Endo-krynologii im. W. Hartwiga, Warszawa 2002; 121-124.
22. Athyros GV, Ganotakis ES, Mikhailidis DO. The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin 2005; 21: 1157-1164.
23. Rabijewski M, Kozakowski J, Zgliczynski W. Współzaleznosc pomiedzy stezeniami testosteronu, siarczanu dehydroepian-drosteronu, insulinoopornoscia i otyłoscia brzuszna u starszych mezczyzn. Endokrynologia Polska 2005; 6: 897-903.
24. Giagulli VA, Kaufman JM, Vermeulen A. Pathogenesis if the decreased androgens levels in obese men. J Clin Endocrinol Metab 1994; 79: 997-1000. (Pubitemid 24342237)
25. Popławska A, Szelachowska M, Zonenberg A, Kinalska I. Ze-spół metaboliczny. Rozdz. 10. W: Kinalska I (red.). Patofizjolo-gia i nastepstwa kliniczne insulinoopornosci 2005; 167-183.
26. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 2003; 26: 575-581. (Pubitemid 36929310)
27. Zmuda JM, Cauley JA, Kriska A. i wsp. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-age men. A 13-year follow-up of former multiple risk intervention trial participants. Am J Epidemiol 1997; 146: 609-617. (Pubitemid 27454548)
28. Khaw KT, Barrett-Connor E. Blood pressure and endogenous testosterone in men; an inverse relationship. J Hypertens 1988; 6: 329-332.
29. Gray A, Feldman HA, McKnley JB i wsp. Age, disease and changing sex hormone levels in middle-aged men; results of the Massachusets Male Aging Study. J Clin Endocrinol Metab 1991; 73: 1016-1025. (Pubitemid 21901140)
30. Khaw K, Barrett-Connor E. Low endogenous androgens predict central adiposity in men. Ann Epi 1992; 2: 675-682.
31. Seidel J, Bjorntrop P, Sjostrom L i wsp. Visceral fat accumulation in men is positively associated with insulin, glucose and C-peptide levels, but negatively with testosterone levels. Metabolism 1990; 39: 897-901. (Pubitemid 20293933)
32. Ravaglia G, Forti P, Maioli F i wsp. The relationship of dehy-droepiandrosterine sulfate (DHEA-S) to endocrine-metabolic parameters and functional status in the oldest-old. Result from an Italian study on healthy free-living over-ninety-year-olds. J Clin Endocrinol Metab 1996; 81: 1171-1178.
33. Field AE, Colditz GA, Willett WC i wsp. The relationship of smoking, age, relative weight, and dietary intake to serum adrenal steroids, sex hormone binding globulin in middle-aged men. J Clin Endocrinol Metab 1994; 79: 1310-1316.
34. Gordon DB, Newitt JA, Shantz LM i wsp. Inhibition of the conversion of 3T3 fibroblast clones to adipocytes by dehydro-epiandrosterone and related anticarcinogenic steroids. Can Research 1986; 46: 13-19.
35. Deslypere JP, Verdonck L, Vermeulen A. Fat tissue: a steroid concentration reservoir and site of steroid metabolism. J Clin Endocrinol Metab 1985; 61: 3389-3395.
36. Kawano H, Yasue H, Kitagawa A i wsp. Dehydroepiandostero-ne supplementation improves endothelial function and insulin sensitivity in men. J Clin Endocrinol Metab 2003; 88: 3190-3195. (Pubitemid 36877493)
37. Buffington CK, Givens JR, Kitabchi AE. Oppositing actions of dehydroepiandrosterone and testosterone on insulin sensitivity. In vivo and in vitro studies of hyperandrogenic females. Diabetes 1991; 40: 693-700.
38. Nestler JE, McClanahan MA, Clore JN i wsp. Insulin inhibits adrenal 17, 20-lyase activity in men. J Clin Endocrinol Metab 1992; 74: 637-642.
39. Barrett-Connor E. Lower endogenous androgens levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Int Med 1992; 117: 807-811.
40. Haffner SM, Mykkanen L, Valdez RA i wsp. Relationship of sex hormones to lipids and lipoproteins In nondiabetic men. J Clin Endocrinol Metab 1993; 77: 1610-1615. (Pubitemid 24000922)
41. LaCroix AZ Yano K, Reed DM. Dehydroepiandrosterone sul-fate, incidence of myocardial infarction, and extent ofatherosl-cerosis in men. Circulation 1992; 86: 1529-1533.
42. Hautanen A, Manttari M, Manninen V i wsp. Adrenal an-drogens and testosterone as coronary risk factors in the Helsinki heart study. Atherosclerosis 1994; 105: 191-200. (Pubitemid 24086509)
43. Adamkiewicz M, Zgliczynski S, Słowinska-Srzednicka J i wsp. The relationship between plasma androgens (dehy-droepiandrosterone sulfate and testosterone) and coronary arteriosclerosis in men: the lower the androgens, the higher the coronary score of arteriosclerosis. The Aging Male 1999; 2: 22-32. (Pubitemid 29305450)
44. Herrington DM. Dehydroepiandrosterone and coronary atherosclerosis. J N York Acad Sci 1995; 774: 271-280. (Pubitemid 26140376)
45. Słowininska-Srzednicka J, Zgliczynski S. Ciswicka-Sznajder-man M i wsp. Decreased plasma dehydroepiandrosterone sul-fate and dihydrotestosterone concentrations in young men after myocardial infarction. Atheroscerosis 1989; 79: 197-205.
46. Hak AE, Witteman JCM, de Jong FH i wsp. Low leves of endogenous androgens increase the risk of atherosclerosis in elderly men; the Rancho Bernardo Study. J Clin Endocrinol Metab 2002; 87: 3632-3639. (Pubitemid 34879505)